Levels of soluble interleukin-2 receptor-α are elevated in serum and ascitic fluid from epithelial ovarian cancer patients

Jean A. Hurteau, H. Uwe Simon, Carol Kurman, Lawrence Rubin, Gordon Mills

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

OBJECTIVE: The purpose of the study was to determine whether ovarian cancer patients have activated lymphocytes as indicated by the presence of soluble interleukin-2 receptor-α and to compare soluble interleukin-2 receptor-α with other markers in ovarian cancer. STUDY DESIGN: Ascites and serum from patients with advanced active ovarian cancer was tested for the presence of elevated levels of soluble interleukin-2 receptor-α and compared with normal controls. Levels of soluble interleukin-2 receptor-α were also compared with levels of CA 125 and macrophage colony-stimulating factor in the same patients, to evaluate the correlation between different markers. RESULTS: Elevated levels of soluble interleukin-2 receptor-α were detected in 86 of 86 (100%) ascites samples and 67 of 85 (79%) serum samples from patients with advanced epithelial ovarian cancer. In contrast, only 12 of 25 (48%) benign ascites samples and one of 88 (1%) serum samples from controls had elevated levels. There was no obvious correlation between levels of soluble interleukin-2 receptor-α and levels of CA 125; however, levels of soluble interleukin-2 receptor-α did correlate with levels of macrophage colony-stimulating factor. Concurrent measurement of serum-soluble interleukin-2α and CA 125 levels detected 100% of patients with epithelial ovarian cancer. CONCLUSION: The detection of elevated levels of soluble interleukin-2 receptor-α in serum and ascites indicates the presence of activated lymphocytes in patients with epithelial ovarian cancer. Ascites and serum levels of soluble interleukin-2 receptor-α are elevated in patients with advanced ovarian cancer and warrant assessment as a potential complementary marker to CA 125 for early detection of ovarian cancer and management of patients with advanced ovarian cancer. (AM J OBSTET GYNECOL 1994;170:918-28.)

Original languageEnglish (US)
Pages (from-to)918-928
Number of pages11
JournalAmerican Journal of Obstetrics and Gynecology
Volume170
Issue number3
DOIs
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Interleukin-2 Receptors
Ascitic Fluid
Ovarian Neoplasms
Ascites
Serum
Macrophage Colony-Stimulating Factor
Lymphocytes
Ovarian epithelial cancer
Early Detection of Cancer
Interleukin-2

Keywords

  • epithelial
  • ovarian
  • Soluble interleukin-2 receptor-α

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Levels of soluble interleukin-2 receptor-α are elevated in serum and ascitic fluid from epithelial ovarian cancer patients. / Hurteau, Jean A.; Simon, H. Uwe; Kurman, Carol; Rubin, Lawrence; Mills, Gordon.

In: American Journal of Obstetrics and Gynecology, Vol. 170, No. 3, 01.01.1994, p. 918-928.

Research output: Contribution to journalArticle

@article{e02fdb9830e9423f96ba034d669bf02f,
title = "Levels of soluble interleukin-2 receptor-α are elevated in serum and ascitic fluid from epithelial ovarian cancer patients",
abstract = "OBJECTIVE: The purpose of the study was to determine whether ovarian cancer patients have activated lymphocytes as indicated by the presence of soluble interleukin-2 receptor-α and to compare soluble interleukin-2 receptor-α with other markers in ovarian cancer. STUDY DESIGN: Ascites and serum from patients with advanced active ovarian cancer was tested for the presence of elevated levels of soluble interleukin-2 receptor-α and compared with normal controls. Levels of soluble interleukin-2 receptor-α were also compared with levels of CA 125 and macrophage colony-stimulating factor in the same patients, to evaluate the correlation between different markers. RESULTS: Elevated levels of soluble interleukin-2 receptor-α were detected in 86 of 86 (100{\%}) ascites samples and 67 of 85 (79{\%}) serum samples from patients with advanced epithelial ovarian cancer. In contrast, only 12 of 25 (48{\%}) benign ascites samples and one of 88 (1{\%}) serum samples from controls had elevated levels. There was no obvious correlation between levels of soluble interleukin-2 receptor-α and levels of CA 125; however, levels of soluble interleukin-2 receptor-α did correlate with levels of macrophage colony-stimulating factor. Concurrent measurement of serum-soluble interleukin-2α and CA 125 levels detected 100{\%} of patients with epithelial ovarian cancer. CONCLUSION: The detection of elevated levels of soluble interleukin-2 receptor-α in serum and ascites indicates the presence of activated lymphocytes in patients with epithelial ovarian cancer. Ascites and serum levels of soluble interleukin-2 receptor-α are elevated in patients with advanced ovarian cancer and warrant assessment as a potential complementary marker to CA 125 for early detection of ovarian cancer and management of patients with advanced ovarian cancer. (AM J OBSTET GYNECOL 1994;170:918-28.)",
keywords = "epithelial, ovarian, Soluble interleukin-2 receptor-α",
author = "Hurteau, {Jean A.} and Simon, {H. Uwe} and Carol Kurman and Lawrence Rubin and Gordon Mills",
year = "1994",
month = "1",
day = "1",
doi = "10.1016/S0002-9378(94)70308-6",
language = "English (US)",
volume = "170",
pages = "918--928",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Levels of soluble interleukin-2 receptor-α are elevated in serum and ascitic fluid from epithelial ovarian cancer patients

AU - Hurteau, Jean A.

AU - Simon, H. Uwe

AU - Kurman, Carol

AU - Rubin, Lawrence

AU - Mills, Gordon

PY - 1994/1/1

Y1 - 1994/1/1

N2 - OBJECTIVE: The purpose of the study was to determine whether ovarian cancer patients have activated lymphocytes as indicated by the presence of soluble interleukin-2 receptor-α and to compare soluble interleukin-2 receptor-α with other markers in ovarian cancer. STUDY DESIGN: Ascites and serum from patients with advanced active ovarian cancer was tested for the presence of elevated levels of soluble interleukin-2 receptor-α and compared with normal controls. Levels of soluble interleukin-2 receptor-α were also compared with levels of CA 125 and macrophage colony-stimulating factor in the same patients, to evaluate the correlation between different markers. RESULTS: Elevated levels of soluble interleukin-2 receptor-α were detected in 86 of 86 (100%) ascites samples and 67 of 85 (79%) serum samples from patients with advanced epithelial ovarian cancer. In contrast, only 12 of 25 (48%) benign ascites samples and one of 88 (1%) serum samples from controls had elevated levels. There was no obvious correlation between levels of soluble interleukin-2 receptor-α and levels of CA 125; however, levels of soluble interleukin-2 receptor-α did correlate with levels of macrophage colony-stimulating factor. Concurrent measurement of serum-soluble interleukin-2α and CA 125 levels detected 100% of patients with epithelial ovarian cancer. CONCLUSION: The detection of elevated levels of soluble interleukin-2 receptor-α in serum and ascites indicates the presence of activated lymphocytes in patients with epithelial ovarian cancer. Ascites and serum levels of soluble interleukin-2 receptor-α are elevated in patients with advanced ovarian cancer and warrant assessment as a potential complementary marker to CA 125 for early detection of ovarian cancer and management of patients with advanced ovarian cancer. (AM J OBSTET GYNECOL 1994;170:918-28.)

AB - OBJECTIVE: The purpose of the study was to determine whether ovarian cancer patients have activated lymphocytes as indicated by the presence of soluble interleukin-2 receptor-α and to compare soluble interleukin-2 receptor-α with other markers in ovarian cancer. STUDY DESIGN: Ascites and serum from patients with advanced active ovarian cancer was tested for the presence of elevated levels of soluble interleukin-2 receptor-α and compared with normal controls. Levels of soluble interleukin-2 receptor-α were also compared with levels of CA 125 and macrophage colony-stimulating factor in the same patients, to evaluate the correlation between different markers. RESULTS: Elevated levels of soluble interleukin-2 receptor-α were detected in 86 of 86 (100%) ascites samples and 67 of 85 (79%) serum samples from patients with advanced epithelial ovarian cancer. In contrast, only 12 of 25 (48%) benign ascites samples and one of 88 (1%) serum samples from controls had elevated levels. There was no obvious correlation between levels of soluble interleukin-2 receptor-α and levels of CA 125; however, levels of soluble interleukin-2 receptor-α did correlate with levels of macrophage colony-stimulating factor. Concurrent measurement of serum-soluble interleukin-2α and CA 125 levels detected 100% of patients with epithelial ovarian cancer. CONCLUSION: The detection of elevated levels of soluble interleukin-2 receptor-α in serum and ascites indicates the presence of activated lymphocytes in patients with epithelial ovarian cancer. Ascites and serum levels of soluble interleukin-2 receptor-α are elevated in patients with advanced ovarian cancer and warrant assessment as a potential complementary marker to CA 125 for early detection of ovarian cancer and management of patients with advanced ovarian cancer. (AM J OBSTET GYNECOL 1994;170:918-28.)

KW - epithelial

KW - ovarian

KW - Soluble interleukin-2 receptor-α

UR - http://www.scopus.com/inward/record.url?scp=0028225499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028225499&partnerID=8YFLogxK

U2 - 10.1016/S0002-9378(94)70308-6

DO - 10.1016/S0002-9378(94)70308-6

M3 - Article

C2 - 8141226

AN - SCOPUS:0028225499

VL - 170

SP - 918

EP - 928

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3

ER -